Invega Trinza Approval History
- FDA approved: Yes (First approved May 18th, 2015)
- Brand name: Invega Trinza
- Generic name: paliperidone palmitate
- Dosage form: Extended-Release Injectable Suspension
- Company: Janssen Pharmaceuticals, Inc.
- Treatment for: Schizophrenia
Invega Trinza (3-month paliperidone palmitate) is a long-acting injectable atypical antipsychotic indicated for the treatment of schizophrenia.
Development History and FDA Approval Process for Invega Trinza
|May 19, 2015||FDA Approves Invega Trinza (paliperidone palmitate) Four-Times-A-Year Treatment for Schizophrenia|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.